CompanyShort-termNeutralDays to weeksBenzingaJNJ

Johnson & Johnson Announces Data From Its VARIPURE, Omny-IRE Trials Demonstrated 100% Of Participants Had Acute Procedural Success; Mean Ablation Rate Of 17.9 Minutes Observed

Reviewed by ClearTape · Source: Benzinga

Key takeaways

JNJ’s new trial data shows a 100% success rate and very low complications, reinforcing the device’s safety and efficiency.
100% acute procedural success
0.4% primary adverse event
17.9 minutes mean ablation time

What happened

Johnson & Johnson (NYSE: JNJ) released new data from its VARIPURE and Omny-IRE trials, showing 100% acute procedural success and a mean ablation time of 17.9 minutes, with only one minor adverse event (0.4%) that resolved without lasting effects.

Why it matters

The trials demonstrate the device’s high effectiveness and safety profile, which could support broader adoption and potentially improve patient outcomes in atrial fibrillation treatment. A short ablation time and low complication rate are attractive metrics for clinicians and payers.

Short-term and longer-term

Short-term. Over the next few days, JNJ stock may react to the trial data, especially if analysts update earnings guidance.

Longer-term. For investors, the data supports JNJ’s long‑term strategy in the cardiac device market.

ClearTape summarizes context in-app. For the full publisher article, use Read original source above.